603 related articles for article (PubMed ID: 16823371)
1. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
[TBL] [Abstract][Full Text] [Related]
2. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
[TBL] [Abstract][Full Text] [Related]
3. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
5. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
7. All in the RNA family.
Davidson BL
Nat Biotechnol; 2006 Aug; 24(8):951-2. PubMed ID: 16900139
[No Abstract] [Full Text] [Related]
8. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.
Zhou J; Li H; Li S; Zaia J; Rossi JJ
Mol Ther; 2008 Aug; 16(8):1481-9. PubMed ID: 18461053
[TBL] [Abstract][Full Text] [Related]
9. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
[TBL] [Abstract][Full Text] [Related]
10. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
Catuogno S; Esposito CL; Giangrande PH
Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
[TBL] [Abstract][Full Text] [Related]
12. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin.
Hussain AF; Tur MK; Barth S
Nucleic Acid Ther; 2013 Jun; 23(3):203-12. PubMed ID: 23544955
[TBL] [Abstract][Full Text] [Related]
13. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
14. A universal protein tag for delivery of SiRNA-aptamer chimeras.
Liu HY; Gao X
Sci Rep; 2013 Nov; 3():3129. PubMed ID: 24196104
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
16. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.
Bagalkot V; Gao X
ACS Nano; 2011 Oct; 5(10):8131-9. PubMed ID: 21936502
[TBL] [Abstract][Full Text] [Related]
17. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
18. Centyrin ligands for extrahepatic delivery of siRNA.
Klein D; Goldberg S; Theile CS; Dambra R; Haskell K; Kuhar E; Lin T; Parmar R; Manoharan M; Richter M; Wu M; Mendrola Zarazowski J; Jadhav V; Maier MA; Sepp-Lorenzino L; O'Neil K; Dudkin V
Mol Ther; 2021 Jun; 29(6):2053-2066. PubMed ID: 33601052
[TBL] [Abstract][Full Text] [Related]
19. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
20. Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.
Thiel KW; Hernandez LI; Dassie JP; Thiel WH; Liu X; Stockdale KR; Rothman AM; Hernandez FJ; McNamara JO; Giangrande PH
Nucleic Acids Res; 2012 Jul; 40(13):6319-37. PubMed ID: 22467215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
